Insiders · LXEO

LXEO insider transactions

Lexeo Therapeutics Inc. (LXEO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for LXEO

• 19d
  Chief Operating Officer Otero Jose Manuel sold $6,606 worth of shares (1,302 units at $5.07), decreasing direct ownership by 0.99% to 130,088 units (SEC Form 4) (for withholding tax)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 19d
  Chief Executive Officer Townsend Richard Nolan sold $16,927 worth of shares (3,342 units at $5.06), decreasing direct ownership by 0.98% to 336,764 units (SEC Form 4) (for withholding tax)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 39d
  SEC Form 4 filed by Director Sepp-Lorenzino Laura

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 39d
  SEC Form 3 filed by new insider Sepp-Lorenzino Laura

  3 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 62d
  SEC Form 4 filed by Townsend Richard Nolan

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 83d
  Chief Executive Officer Townsend Richard Nolan was granted 2,623 shares, increasing direct ownership by 0.67% to 395,106 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 83d
  Chief Operating Officer Otero Jose Manuel was granted 5,930 shares, increasing direct ownership by 5% to 131,390 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 108d
  Chief Operating Officer Otero Jose Manuel sold $19,294 worth of shares (3,016 units at $6.40), decreasing direct ownership by 2% to 125,460 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 108d
  Chief Executive Officer Townsend Richard Nolan sold $64,924 worth of shares (10,173 units at $6.38), decreasing direct ownership by 3% to 392,483 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 108d
  Amendment: Chief Operating Officer Otero Jose Manuel sold $6,684 worth of shares (721 units at $9.27), decreasing direct ownership by 1% to 63,476 units (SEC Form 4)

  4/A - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 111d
  Chief Medical Officer Bhalla Narinder Pal was granted 49,500 shares (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 122d
  Chief Financial Officer Tamayo Louis Edward was granted 44,665 shares, increasing direct ownership by 99% to 89,665 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 122d
  Chief Executive Officer Townsend Richard Nolan was granted 161,665 shares, increasing direct ownership by 67% to 402,656 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 122d
  Chief Operating Officer Otero Jose Manuel was granted 65,000 shares, increasing direct ownership by 102% to 128,476 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 123d
  SEC Form 3 filed by new insider Bhalla Narinder Pal

  3 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 200d
  Chief Executive Officer Townsend Richard Nolan sold $10,447 worth of shares (1,127 units at $9.27), decreasing direct ownership by 0.47% to 240,991 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 200d
  Chief Medical Officer Adler Eric sold $5,701 worth of shares (615 units at $9.27), decreasing direct ownership by 0.84% to 72,646 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 200d
  Chief Development Officer See Tai Sandi sold $3,578 worth of shares (386 units at $9.27), decreasing direct ownership by 0.59% to 65,476 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 200d
  Chief Legal Officer Robertson Jenny sold $5,089 worth of shares (549 units at $9.27), decreasing direct ownership by 0.80% to 68,381 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 200d
  Chief Technical Officer Otero Jose Manuel sold $6,684 worth of shares (721 units at $9.27), decreasing direct ownership by 1% to 63,476 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 234d
  Chief Development Officer See Tai Sandi was granted 10,890 shares and sold $34,767 worth of shares (3,888 units at $8.94), increasing direct ownership by 12% to 65,862 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 234d
  Chief Legal Officer Robertson Jenny was granted 9,900 shares and sold $31,530 worth of shares (3,526 units at $8.94), increasing direct ownership by 10% to 68,930 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 234d
  Chief Technical Officer Otero Jose Manuel was granted 5,940 shares and sold $18,913 worth of shares (2,115 units at $8.94), increasing direct ownership by 6% to 64,197 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 234d
  Chief Medical Officer Adler Eric was granted 9,570 shares and sold $30,242 worth of shares (3,382 units at $8.94), increasing direct ownership by 9% to 73,261 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 234d
  Chief Executive Officer Townsend Richard Nolan was granted 33,000 shares and sold $117,436 worth of shares (13,133 units at $8.94), increasing direct ownership by 9% to 242,118 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 265d
  Chief Executive Officer Townsend Richard Nolan was granted 2,193 shares, increasing direct ownership by 1.00% to 222,251 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 271d
  Amendment: Chief Executive Officer Townsend Richard Nolan sold $5,205 worth of shares (1,115 units at $4.67), decreasing direct ownership by 0.50% to 220,058 units (SEC Form 4)

  4/A - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 278d
  Chief Financial Officer Tamayo Louis Edward was granted 45,000 shares (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 285d
  SEC Form 3 filed by new insider Tamayo Louis Edward

  3 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 292d
  Chief Technical Officer Otero Jose Manuel sold $13,294 worth of shares (2,848 units at $4.67), decreasing direct ownership by 5% to 60,372 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 292d
  Chief Legal Officer Robertson Jenny sold $2,530 worth of shares (542 units at $4.67), decreasing direct ownership by 0.86% to 62,556 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 292d
  Chief Medical Officer Adler Eric sold $2,838 worth of shares (608 units at $4.67), decreasing direct ownership by 0.90% to 67,073 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 292d
  Chief Executive Officer Townsend Richard Nolan sold $12,767 worth of shares (2,735 units at $4.67), decreasing direct ownership by 1% to 220,058 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 292d
  Chief Development Officer See Tai Sandi sold $1,783 worth of shares (382 units at $4.67), decreasing direct ownership by 0.64% to 58,860 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 343d
  SEC Form 4 filed by Director Van Hauwermeiren Timothy

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 343d
  SEC Form 4 filed by Director Tanguler Tolga

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 343d
  SEC Form 4 filed by Director Cholmondeley Paula H

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 343d
  SEC Form 4 filed by Director Altschuler Steven

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 343d
  SEC Form 4 filed by Director Cooperstone Brenda

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 343d
  SEC Form 4 filed by Director Diaz Reinaldo M

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 343d
  SEC Form 4 filed by Director Agger Mette Kirstine

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 384d
  Chief Medical Officer Adler Eric sold $1,623 worth of shares (585 units at $2.77), decreasing direct ownership by 0.86% to 67,681 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 384d
  Chief Legal Officer Robertson Jenny sold $1,445 worth of shares (521 units at $2.77), decreasing direct ownership by 0.82% to 63,098 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 384d
  Chief Executive Officer Townsend Richard Nolan sold $2,979 worth of shares (1,074 units at $2.77), decreasing direct ownership by 0.48% to 221,173 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 384d
  Chief Development Officer See Tai Sandi sold $1,018 worth of shares (367 units at $2.77), decreasing direct ownership by 0.62% to 59,242 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 425d
  Chief Technical Officer Otero Jose Manuel was granted 5,720 shares, increasing direct ownership by 10% to 63,220 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 425d
  Chief Legal Officer Robertson Jenny was granted 5,720 shares, increasing direct ownership by 10% to 63,619 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 425d
  Chief Development Officer See Tai Sandi was granted 5,720 shares, increasing direct ownership by 11% to 59,609 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 433d
  Chief Executive Officer Townsend Richard Nolan was granted 2,128 shares, increasing direct ownership by 0.97% to 222,247 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 472d
  Chief Executive Officer Townsend Richard Nolan sold $19,091 worth of shares (4,326 units at $4.41), decreasing direct ownership by 2% to 220,119 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 472d
  Chief Development Officer See Tai Sandi sold $6,558 worth of shares (1,486 units at $4.41), decreasing direct ownership by 3% to 53,889 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 472d
  Chief Medical Officer Adler Eric sold $10,410 worth of shares (2,359 units at $4.41), decreasing direct ownership by 3% to 68,266 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 472d
  Chief Legal Officer Robertson Jenny sold $9,272 worth of shares (2,101 units at $4.41), decreasing direct ownership by 4% to 57,899 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 502d
  Chief Financial Officer Rasbach Kyle was granted 40,875 shares (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 514d
  Chief Legal & Admin Officer Robertson Jenny was granted 36,250 shares, increasing direct ownership by 153% to 60,000 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 514d
  Chief Executive Officer Townsend Richard Nolan was granted 103,750 shares, increasing direct ownership by 86% to 224,445 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 514d
  Chief Development Officer See Tai Sandi was granted 38,750 shares, increasing direct ownership by 233% to 55,375 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 514d
  Chief Technical Officer Otero Jose Manuel was granted 26,250 shares, increasing direct ownership by 84% to 57,500 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 514d
  Chief Medical Officer Adler Eric was granted 43,750 shares, increasing direct ownership by 163% to 70,625 units (SEC Form 4)

  4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
• 528d
  SEC Form 3 filed by new insider Rasbach Kyle

  3 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)